NewsOur reputation as a national leader in the field of prosecuting class action, commercial litigation, and qui tam cases makes headlines and shapes precedent across the country.Major media outlets and industry publications regularly consult Berger Montague lawyers as knowledgeable and insightful sources to comment on regulation, legislation, precedent-setting cases, and industry developments.To learn about the most recent activities of the firm and its attorneys, read on. If you are a member of the news media seeking to develop a story concerning a legal subject or newsworthy case, please contact Katherine Nolen at (215) 875-3042 or firstname.lastname@example.org.
Third False Claims Act Settlement for Medically Unnecessary Stent and Cardiac Procedures at Tennessee Hospitals
In a False Claims Act case in which the United States declined to intervene, Berger Montague announces that Regional Hospital of Jackson, Tennessee, has agreed to pay $510,000 to resolve claims arising from medically unnecessary stent and other cardiac procedures performed by one of its interventional cardiologists.
AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to Resolve False Claims Act Allegations Made By Whistleblower Ronald Streck
Berger Montague, a full-spectrum class action and complex civil litigation law firm with one of the largest and most successful whistleblower practices in the U.S, joined co-counsel Faruqi and Faruqi, LLP in settling three separate but related whistleblower lawsuits against pharmaceutical manufacturers AstraZeneca Pharmaceuticals LP, Cephalon, Inc., and Biogen, Inc., for a total of $55.5 million, plus statutory fees.
Appellate Victory for Class in $1B Plutonium Contamination Suit Against Dow Chemical Co. and the Former Rockwell International Corp.
On a second trip to the Tenth Circuit Court of Appeals, Plaintiffs secured a victory in Merilyn Cook et al. v. Rockwell International Corporation et al., case number 14-1112, with the case being sent back to the district court, which in 2008, ordered the companies to pay a total of $926 million in damages, including $549 million in prejudgment interest due to extensive pre-trial delays.
Berger Montague is proud to announce that the firm has been ranked as a Top-Tier Firm for Antitrust: Civil Litigation and Class Actions in the United States by The Legal 500. Since its founding in 1970, Berger Montague has litigated many of the most significant civil antitrust cases alleging price fixing and monopoly abuse.
Berger Montague would like to congratulate the 27 attorneys who have been named 2015 Super Lawyers and Rising Stars by Thomson Reuters. Employment Law Chair Shanon Carson was also listed in the Top 100 Super Lawyers of Pennsylvania and the Top 100 Super Lawyers of Philadelphia.
Berger Montague is proud to announce that the firm has been ranked Band 2 by Chambers USA for Antitrust in Pennsylvania. Since its founding in 1970, Berger Montague has litigated many of the most significant civil antitrust cases alleging price fixing and monopoly abuse.
Berger Montague Announces False Claims Act Settlement for Medically Unnecessary Stent and Cardiac Procedures
In a False Claims Act case in which the United States declined to intervene, Berger Montague announces that Jackson-Madison County General Hospital of Jackson, Tennessee, has agreed to pay $1,328,465 to resolve claims arising from medically unnecessary stent and other cardiac procedures performed by one of its interventional cardiologists.
Counsel for Plaintiffs: $36 Million Settlement Has Been Reached With Northern Trust Company and Northern Trust Investments, N.A.
The lawsuit alleges that Northern Trust breached its duties to retirement plans and their participants and beneficiaries. According to Plaintiffs, Northern Trust imprudently invested collateral received from securities lending activities and, in addition, charged impermissibly high fees.
This article presents a case study of a CFO’s accounting fraud that led him to prison. The scheme was a securities fraud aimed at investors. It involved ghost revenues, fictitious invoices and shipping documents, cost-of-good sold entries that were delayed or avoided altogether, and pulling otherwise legitimate revenue into earlier accounting periods.
In recent years, a new standard appears to have emerged regarding class certification. Courts have largely dismissed the notion – originally derived from Eisen v. Carlisle & Jacquelin – that they cannot resolve issues relevant to the merits in deciding whether to certify a class.